In vivo and in vitro effects of tracheloside on colorectal cancer cell proliferation and metastasis

Abstract

Recent research suggests a relationship between cancer progression and oxidative mech-anisms. Among the phenolic compounds such as tracheloside (TCS) are a major bioactive compound that can combat oxidant stress‐related chronic diseases and that also displays anti‐tumor activity. Although TCS can inhibit mammalian carcinoma, its effects on colorectal cancer (CRC) have not been clarified. The purpose of this study was to investigate the effects of TCS on the proliferation of CRC cells, the metastasis of CT26 cells, and the molecular mechanisms related to TCS in vitro and in vivo. A cell viability assay showed that TCS inhibited the proliferation of CRC cells. TCS‐treated CT26 cells were associated with the upregulation of p16 as well as the downregulation of cyclin D1 and CDK4 in cell cycle arrest. In addition, TCS induced apoptosis of CT26 cells through mitochondria‐mediated apoptosis and regulation of the Bcl‐2 family. Expression of epithelial–mes-enchymal transition (EMT) markers was regulated by TCS treatment in CT26 cells. TCS significantly inhibited the lung metastasis of CT26 cells in a mouse model. These results suggest that TCS, by inducing cell cycle arrest and apoptosis through its anti‐oxidant properties, is a novel therapeutic agent that inhibits metastatic phenotypes of murine CRC cells.